Eris Lifesciences [ERIS] vs Poly Medicure [POLYMED] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eris Lifesciences Ltd. wins in 13 metrics, Poly Medicure Ltd. wins in 7 metrics, with 0 ties. Eris Lifesciences Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eris Lifesciences Ltd. | Poly Medicure Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.25 | 43.53 | Poly Medicure Ltd. |
| Price-to-Book Ratio | 6.15 | 5.17 | Poly Medicure Ltd. |
| Debt-to-Equity Ratio | 68.19 | 8.17 | Poly Medicure Ltd. |
| PEG Ratio | 2.33 | -2.49 | Eris Lifesciences Ltd. |
| EV/EBITDA | 17.91 | 31.35 | Eris Lifesciences Ltd. |
| Profit Margin (TTM) | 14.06% | 19.51% | Poly Medicure Ltd. |
| Operating Margin (TTM) | 26.38% | 16.70% | Eris Lifesciences Ltd. |
| EBITDA Margin (TTM) | 26.38% | 16.70% | Eris Lifesciences Ltd. |
| Return on Equity | 10.75% | 12.24% | Poly Medicure Ltd. |
| Return on Assets (TTM) | 5.00% | 10.60% | Poly Medicure Ltd. |
| Free Cash Flow (TTM) | $9.10B | $-906.06M | Eris Lifesciences Ltd. |
| Dividend Yield | 0.41% | 0.33% | Eris Lifesciences Ltd. |
| 1-Year Return | -21.75% | -31.00% | Eris Lifesciences Ltd. |
| Price-to-Sales Ratio (TTM) | 6.31 | 8.48 | Eris Lifesciences Ltd. |
| Enterprise Value | $217.40B | $140.85B | Eris Lifesciences Ltd. |
| EV/Revenue Ratio | 7.09 | 7.91 | Eris Lifesciences Ltd. |
| Gross Profit Margin (TTM) | 72.12% | 36.69% | Eris Lifesciences Ltd. |
| Revenue per Share (TTM) | $225 | $175 | Eris Lifesciences Ltd. |
| Earnings per Share (Diluted) | $31.54 | $34.18 | Poly Medicure Ltd. |
| Beta (Stock Volatility) | -0.14 | -0.08 | Eris Lifesciences Ltd. |
Eris Lifesciences Ltd. vs Poly Medicure Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -1.44% | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% |
| Poly Medicure Ltd. | -1.40% | 9.26% | 0.80% | 20.33% | -19.36% | -13.29% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
| Poly Medicure Ltd. | -31.00% | 33.68% | 70.32% | 703.44% | 4,602.06% | 4,602.06% |
Performance & Financial Health Analysis: Eris Lifesciences Ltd. vs Poly Medicure Ltd.
| Metric | ERIS | POLYMED |
|---|---|---|
| Market Information | ||
| Market Cap | ₹193.36B | ₹151.00B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 174,049 | 83,624 |
| 90 Day Avg. Volume | 106,619 | 159,317 |
| Last Close | ₹1,384.40 | ₹1,510.90 |
| 52 Week Range | ₹1,200.00 - ₹1,900.00 | ₹1,182.00 - ₹2,316.60 |
| % from 52W High | -27.14% | -34.78% |
| All-Time High | ₹1,910.00 (Jun 09, 2025) | ₹3,357.80 (Oct 28, 2024) |
| % from All-Time High | -27.52% | -55.00% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.16% |
| Quarterly Earnings Growth | 0.19% | -0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.20% |
| Operating Margin (TTM) | 0.26% | 0.17% |
| Return on Equity (TTM) | 0.11% | 0.12% |
| Debt to Equity (MRQ) | 68.19 | 8.17 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹226.84 | ₹287.91 |
| Cash per Share (MRQ) | ₹5.49 | ₹108.21 |
| Operating Cash Flow (TTM) | ₹7.57B | ₹2.95B |
| Levered Free Cash Flow (TTM) | ₹3.52B | ₹3.39B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.41% | 0.33% |
| Last 12-Month Dividend | ₹7.35 | ₹6.50 |
Valuation & Enterprise Metrics Analysis: Eris Lifesciences Ltd. vs Poly Medicure Ltd.
| Metric | ERIS (Apr 24, 2026) | POLYMED (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.25 | 43.53 |
| Forward P/E | 27.76 | 37.61 |
| PEG Ratio | 2.33 | -2.49 |
| Price to Sales (TTM) | 6.31 | 8.48 |
| Price to Book (MRQ) | 6.15 | 5.17 |
| Market Capitalization | ||
| Market Capitalization | ₹193.36B | ₹151.00B |
| Enterprise Value | ₹217.40B | ₹140.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.09 | 7.91 |
| Enterprise to EBITDA | 17.91 | 31.35 |
| Risk & Other Metrics | ||
| Beta | -0.14 | -0.08 |
| Book Value per Share (MRQ) | ₹226.84 | ₹287.91 |
Financial Statements Comparison: Eris Lifesciences Ltd. vs Poly Medicure Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ERIS (2025) | POLYMED (2025) |
|---|---|---|
| Revenue/Sales | 28.79B | 16.55B |
| Cost of Goods Sold | 7.30B | 7.06B |
| COGS % of Revenue | 25.4% | 42.7% |
| Gross Profit | 21.49B | 9.49B |
| Gross Margin | 74.6% | 57.3% |
| Research & Development | 24.40M | 245.71M |
| Operating Income (EBIT) | 7.03B | 3.80B |
| Operating Margin | 24.4% | 23.0% |
| EBITDA | 10.33B | 5.10B |
| EBITDA Margin | 35.9% | 30.8% |
| Pre-Tax Income | 4.89B | 4.53B |
| Pre-Tax Income % of Revenue | 17.0% | 27.3% |
| Income Tax | 1.14B | 1.14B |
| Income Tax % of Revenue | 4.0% | 6.9% |
| Net Income (Profit) | 3.75B | 3.39B |
| Profit Margin | 13.0% | 20.5% |
Balance Sheet & Liquidity Metrics
| Metric | ERIS (2025) | POLYMED (2025) |
|---|---|---|
| Cash & Equivalents | 2.00B | 86.99M |
| Total Current Assets | 12.23B | 19.17B |
| Total Current Assets % of Revenue | 42.5% | 115.8% |
| Total Current Liabilities | 13.81B | 3.70B |
| Total Current Liabilities % of Revenue | 48.0% | 22.4% |
| Long-Term Debt | 17.82B | 7.71M |
| Long-Term Debt % of Revenue | 61.9% | 0.0% |
| Total Shareholders Equity | 32.72B | 27.66B |
| Retained Earnings | 27.93B | 10.14B |
| Retained Earnings % of Revenue | 97.0% | 61.2% |
| Property, Plant & Equipment | 2.36B | 24.01M |
Cash Flow Statement Comparison
| Metric | ERIS (2025) | POLYMED (2025) |
|---|---|---|
| Operating Cash Flow | 7.57B | 2.95B |
| Operating Cash Flow % of Revenue | 26.3% | 17.8% |
| Capital Expenditures | -1.55B | -3.30B |
| Free Cash Flow | 9.10B | -906.06M |
| FCF Margin | 31.6% | -5.5% |
| Debt Repayment | -18.34B | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ERIS | POLYMED |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 138.54M | 101.36M |
| Float Shares | 43.42M | 33.56M |
| % Held by Insiders | 68.05% | 66.86% |
| % Held by Institutions | 21.83% | 18.77% |
| % Held by Public | 10.12% | 14.37% |
Dividend Analysis & Yield Comparison: Eris Lifesciences Ltd. vs Poly Medicure Ltd.
| Metric | ERIS | POLYMED |
|---|---|---|
| Last 12-Month Dividend | ₹7.35 | ₹6.50 |
| Last 12-Month Dividend Yield | 0.41% | 0.33% |
| 3-Year Avg Annual Dividend | ₹4.90 | ₹3.17 |
| 3-Year Avg Dividend Yield | 0.82% | 0.18% |
| 3-Year Total Dividends | ₹14.70 | ₹9.50 |
| Ex-Dividend Date | Feb 13, 2025 | Sep 18, 2025 |